# Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

> **NCT03448835** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Stomach Cancer
- Gastro Esophageal Junction Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03448835
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-07
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03448835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03448835, "Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03448835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*